Mirati Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2012 to 2022

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Mirati Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2012 to 2022.
  • Mirati Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2023 was -$162M, a 6.72% increase year-over-year.
  • Mirati Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2023 was -$726M, a 1.64% increase year-over-year.
  • Mirati Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$741M, a 27.3% decline from 2021.
  • Mirati Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$582M, a 62.5% decline from 2020.
  • Mirati Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$358M, a 67.8% decline from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.